Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Banting Postdoctoral Fellowship Program

Direct Payment

$140,000.00

Glutamate excitotoxicity drives neurological death in leptomeningeal metastasis

EF 2022-23

Résumé
The leptomeninges consist of microscopic tissue layers that cover the brain and contain the circulating spinal fluid. The spread of cancer cells into the leptomeningeal space or leptomeningeal metastasis (LM) is a fatal complication of cancer, most commonly seen in breast, lung, and melanoma patients. Unlike metastatic cancer within the brain, LM does not result in increased brain swelling or local brain pressure and yet, patients succumb to their disease due to neurological complications in less than 5 months from diagnosis. Therefore, determining the cause of neurological death in LM may offer dedicated therapies and extend survival. We hypothesize that astrocytes react to cancer cells in the leptomeningeal space leading to impaired uptake of the excitatory neurotransmitter glutamate, which then fuels the growth of cancer cells and results in neurological death in LM. By leveraging single cell RNA-sequencing data and multiphoton intravital imaging at a single cell resolution, we will evaluate the microenvironmental determinants of neurological death in LM. We have pioneered preclinical models of LM, which recapitulate the human disease. Combined with our unprecedented access to clinical samples of LM, we will be able to characterize the glutamate receptor profile and metabolic machinery in astrocytes and cancer cells, visualize real-time astrocyte-cancer cell interactions in living mice, and determine outcomes in preclinical models treated with selective inhibitors of glutamate biosynthesis and receptors unique to cancer cells. Ultimately, our work will provide a regional, structural, cellular, and molecular understanding of neurological death in LM, for which patients are currently treated with palliation alone and lack even a single effective therapeutic intervention.
Programme
Banting Postdoctoral Fellowship Program
Bénéficiaire
Emplacement
New York, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
471420
Name
Manoranjan Branavan
Region
New York
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
Glutamate excitotoxicity drives neurological death in leptomeningeal metastasis
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Brain Metastasis; Breast Cancer; Cancer Neuroscience; Central Nervous System Metastasis; Excitotoxicity; Glutamate; Leptomeningeal Metastasis; Lung Cancer; Melanoma; Reactive Astrocytes
Abstract
The leptomeninges consist of microscopic tissue layers that cover the brain and contain the circulating spinal fluid. The spread of cancer cells into the leptomeningeal space or leptomeningeal metastasis (LM) is a fatal complication of cancer, most commonly seen in breast, lung, and melanoma patients. Unlike metastatic cancer within the brain, LM does not result in increased brain swelling or local brain pressure and yet, patients succumb to their disease due to neurological complications in less than 5 months from diagnosis. Therefore, determining the cause of neurological death in LM may offer dedicated therapies and extend survival. We hypothesize that astrocytes react to cancer cells in the leptomeningeal space leading to impaired uptake of the excitatory neurotransmitter glutamate, which then fuels the growth of cancer cells and results in neurological death in LM. By leveraging single cell RNA-sequencing data and multiphoton intravital imaging at a single cell resolution, we will evaluate the microenvironmental determinants of neurological death in LM. We have pioneered preclinical models of LM, which recapitulate the human disease. Combined with our unprecedented access to clinical samples of LM, we will be able to characterize the glutamate receptor profile and metabolic machinery in astrocytes and cancer cells, visualize real-time astrocyte-cancer cell interactions in living mice, and determine outcomes in preclinical models treated with selective inhibitors of glutamate biosynthesis and receptors unique to cancer cells. Ultimately, our work will provide a regional, structural, cellular, and molecular understanding of neurological death in LM, for which patients are currently treated with palliation alone and lack even a single effective therapeutic intervention.
Competitiondate
202209
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Manoranjan, Branavan
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~